Skip to the page content
Your donations
Passes our checks

Pharmaceutical Research and Manufacturers of America Fnd Inc

EIN 52-6063009 · Washington, DC

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthGood89 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE.

Income
$4.9 million
Spending
$5.2 million
Spent on programs
89%
Reserves
62.9 months of spending
Largest source of income
donations and private grants, 58%
Employees
4
Volunteers
85
Highest pay
$613,926, president

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Good: 89 out of 100.

  • Reserves

    35 of 35

    Spendable reserves would cover 62.9 months of spending.

  • Debt

    20 of 20

    It owes 5% of what it owns.

  • Living within its means

    4 of 15

    Spending exceeded income by 6% of income.

  • Income trend

    15 of 15

    Income rose 14% on the year before.

  • Spending floor

    15 of 15

    89% of spending went to programs and raising each dollar of donations cost 0 cents.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100.

  • Independent board

    25 of 25

    9 of 9 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (9)
  1. $1.3 million spent. Drug Discovery - funds early career academic scientists who are pioneering new approaches to drug discovery. We support research projects that have the potential to make a significant impact for patients. By funding the drug discovery research of promising young scientists, the Foundation helps accelerate the identification of new therapeutic compounds and modalities while building a talent base to support innovation across the biopharmaceutical industry.
  2. $1.1 million spent. Drug Delivery - Funds researchers studying ways to optimize drug composition, dosage, and delivery to make treatments safer, more effective, and easier to manage for patients.
  3. $901,315 spent. Value Assessment-Health Outcomes Research (VA-HOR) - supports early career researchers engaged in a multidisciplinary, collaborative research that investigates challenges and potential solutions related to evaluating the delivery, safe use, effectiveness, and value (clinical, patient-centered, and economic) of medicines and other health care interventions.
  4. $864,045 spent. Translational Medicine - Funds novel research that uses the "bedside to bench" approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation supports early career researchers focused on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.
  5. $410,148 spent. DIGITAL HEALTH TECHNOLOGIES - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING.
  6. $61,365 spent. Other Program Expenses
  7. (Expenses $ 864,045 including grants of $ 693,309)(Revenue $ 0) Translational Medicine - Funds novel research that uses the "bedside to bench" approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation supports early career researchers focused on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.
  8. (Expenses $ 410,148 including grants of $ 333,336)(Revenue $ 0) DIGITAL HEALTH TECHNOLOGIES - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING.
  9. (Expenses $ 61,365 including grants of $ 0)(Revenue $ 0) Other Program Expenses

Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since November 1965.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.

  7. Could it be confused with another charity? Worth knowing.

    A much larger organization has a similar name: Pharmaceutical Research and Manufacturers of America (Washington, DC), EIN 53-0241211. If that is the one you meant, check the EIN before giving.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.